XIX International AIDS Conference


SUSA28 Community Scientific Literacy Workshop "Towards an HIV Cure"
  Non-Commercial Satellite
Venue: Session Room 8
Time: 22.07.2012, 15:45 - 17:45
Co-Chairs: Mark Harrington, United States
Steven G. Deeks, United States
Organiser: The International AIDS Society and the Treatment Action Group, in partnership with Towards an HIV Cure Advisory Board
 
 
Objectives: To introduce community delegates to the latest information on research into curing HIV infection, including: . Obstacles to curing HIV infection, evidence that a cure may be possible, and current approaches under study . Ethics and informed consent issues in cure research . Global advocacy update: the IAS Global Strategy and other efforts to accelerate the development of an accessible, scalable cure for HIV

15:45

Powerpoint
Cure research overview


S. Lewin, Australia

16:15

Powerpoint
Berlin Patient, CCR5 modification & research participation -


M. Sharp, United States

16:35

Powerpoint
Ethics and informed consent issues in cure research


D. Evans, United States

16:55

Powerpoint
European community survey on HIV Cure


F. Verdult, Netherlands

17:05

Powerpoint
Advocacy Issues


M. Penicaud, France

Powerpoints presentations
Cure research overview - Sharon Lewin

Berlin Patient, CCR5 modification & research participation - - Matt Sharp

Ethics and informed consent issues in cure research - David Evans

European community survey on HIV Cure - Fred Verdult

Advocacy Issues - Marie-Capucine Penicaud



Rapporteur report

Track B report by Dr. John McKinnon


Cure Research Overview, by Sharon Lewin
The major barriers for cure are: latently infected T cells, residual viral replication, anatomic reservoirs with long lived cells and variable ART penetration.
Strategies: a. Eliminate latently infected cells by reactivation of the virus. SAHA and other compounds in clinical studies. b. Eliminate viral replication- several ART intensification strategies failed. Intensify immune response with IL-7 or with DNA vaccines. Better tissue drug delivery. Decrease immune activation.Making cells resistance to HIV. CCR5 gene knockout with zinc finger nuclease strategy. Action: Multiple studies and strategies currently being evaluated and will have more information in the next few years. Summary: HIV cure is a complex and difficult undertaking. Likely more than one strategy will be required to achieve cure and trials are currently in early stages.

2. Berlin patient, CCR5 Modification & Research Participation, by Matt Sharp
Action: The need for direct and active involvement of HIV activist, HIV peers and researchers in informing and education the HIV potential participants in cure trials. Summary: Cure trial participation will require significant participation by the HIV community, better description of the studies and education. Researcher will need to address several potential issues with this kind of trials.

3. Ethics and Informed consent issues in cure research, by David Evans
Informed consent issues are important as poor understanding of difficult concepts is likely and participant comprehension tends to be poor. Issue of altruism will be a factor, as little direct benefit is expected for participants of early trials. Action: Ethical issues regarding HIV cure trials, the study participants, and informed consent will need to be addressed as new trials are developed. Summary: Ethical issues for cure trials tend to be complex and will require improve patient understanding of the benefits and risks, with repeated efforts to ensure patient understanding.

4. European community survey on HIV cure, by Fred Verdult
72% of HIV+ patients felt a HIV cure was important for them and the primary reason was the future risk of getting side effects or becoming ill (70%), followed by the negative impact of HIV in their general health (46%). Traditional factors associated with reasons for cure, as longevity were lower (9th). 95% wanted a sterilizing cure with no further risk of acquiring HIV again. Functional cures were less desirable. Action: Importance of evaluating the patient’s own expectations and preference for enrollment in cure trials and which strategies will be better received. Summary: HIV patient’s desire for sterilizing cure over functional cure will impact evaluations of cure strategies and the reasons for seeking an HIV cure differ what researchers had previously considered.

5. Advocacy Issues, by Marie-Capucine Penicaud
The presentation nicely reviewed the IAS HIV cure strategies and focus, as well as providing information on several sessions which will focus on HIV cure during this meeting. Action: Recommended attendance to several presentations during this meeting. Summary: IAS cure strategies are available in the IAS website and focus on a safe, scalable and affordable cure strategy. Several sessions covering this topic during IAS were recommended.


   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2012 International AIDS Society